ANTIBODY MOLECULES TO PD-1 AND USES THEREOF

Title:

ANTIBODY MOLECULES TO PD-1 AND USES THEREOF

Document Type and Number:

Japanese Patent JP2022180567

Kind Code:

A

Abstract:

To provide antibody molecules that specifically bind to PD-1, where the antibody molecules can be used to treat or prevent cancerous or infectious conditions and disorders.SOLUTION: Provided is an anti-PD-I antibody molecule for use at a dose of about 300 mg to 400 mg once every three weeks or once every four weeks in treating a cancer in a subject, where the anti-PD-I antibody molecule comprises a specific amino acid sequence.SELECTED DRAWING: None

Inventors:

Sanella Brick
Danny Roland Howard Jr.
John Scott Cameron
Glen Dranoff

Application Number:

JP2022152739A

Publication Date:

December 06, 2022

Filing Date:

September 26, 2022

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Novartis Age

International Classes:

C07K16/30; A61K31/337; A61K38/20; A61K39/395; A61K45/00; A61P1/04; A61P1/16; A61P1/18; A61P11/00; A61P13/08; A61P13/12; A61P15/00; A61P17/00; A61P19/00; A61P25/00; A61P35/00; A61P35/02; A61P43/00

Attorney, Agent or Firm:

Hiroshi Kobayashi
Eiji Katayama
Norio Omori

Previous Patent: Programs, communication terminals and communication systems

Next Patent: Styrene-based resin composition, flame-retardant styrene-based resin composition, molding, and patch...